Is ATHX or PRPH more profitable?

Athersys has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Athersys' return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% ProPhase Labs -825.01% -482.05% -88.90%

Do analysts rate PRPH or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PRPH or PRFX?

In the previous week, PainReform had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for PainReform and 2 mentions for ProPhase Labs. PainReform's average media sentiment score of 0.94 beat ProPhase Labs' score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRPH or CMND?

In the previous week, Clearmind Medicine had 6 more articles in the media than ProPhase Labs. MarketBeat recorded 8 mentions for Clearmind Medicine and 2 mentions for ProPhase Labs. Clearmind Medicine's average media sentiment score of 0.61 beat ProPhase Labs' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Clearmind Medicine 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CERO or PRPH?

CERo Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 336,978.65%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CERo Therapeutics is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to CERO or PRPH?

In the previous week, CERo Therapeutics and CERo Therapeutics both had 2 articles in the media. CERo Therapeutics' average media sentiment score of 1.22 beat ProPhase Labs' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CERo Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PRPH or BPTSY?

Biophytis has lower revenue, but higher earnings than ProPhase Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProPhase Labs $5.06M 0.03 -$53.36M -$2.25 N/A Biophytis N/A N/A -$18.43M N/A N/A

ProPhase Labs (PRPH) Competitors

$0.0090 0.00 (-10.00%)

As of 10/9/2026 02:37 PM Eastern

Compare

PRPH vs. ATHX, PRFX, CMND, CERO, and BPTSY

Should you buy ProPhase Labs stock or one of its competitors? ProPhase Labs's main competitors and comparable companies include Athersys (ATHX), PainReform (PRFX), Clearmind Medicine (CMND), CERo Therapeutics (CERO), and Biophytis (BPTSY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ProPhase Labs compare to Athersys?

Athersys (NASDAQ:ATHX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

19.4% of Athersys shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Athersys has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Athersys' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market.

In the previous week, ProPhase Labs had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
ProPhase Labs	Neutral

ProPhase Labs has higher revenue and earnings than Athersys. ProPhase Labs is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A

Summary

ProPhase Labs beats Athersys on 6 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to PainReform?

ProPhase Labs (NASDAQ:PRPH) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PainReform had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for PainReform and 2 mentions for ProPhase Labs. PainReform's average media sentiment score of 0.94 beat ProPhase Labs' score of 0.00 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ProPhase Labs has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, PainReform has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

PainReform has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. PainReform's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
PainReform	N/A	N/A	N/A

PainReform has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A
PainReform	$20K	38.23	-$5.02M	-$736.66	N/A

Summary

PainReform beats ProPhase Labs on 12 of the 14 factors compared between the two stocks.

How does ProPhase Labs compare to Clearmind Medicine?

ProPhase Labs (NASDAQ:PRPH) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Clearmind Medicine has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Clearmind Medicine's return on equity of -88.53% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Clearmind Medicine	N/A	-88.53%	-61.62%

In the previous week, Clearmind Medicine had 6 more articles in the media than ProPhase Labs. MarketBeat recorded 8 mentions for Clearmind Medicine and 2 mentions for ProPhase Labs. Clearmind Medicine's average media sentiment score of 0.61 beat ProPhase Labs' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clearmind Medicine	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProPhase Labs has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Clearmind Medicine has lower revenue, but higher earnings than ProPhase Labs. Clearmind Medicine is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$40.55	N/A

Summary

Clearmind Medicine beats ProPhase Labs on 8 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

CERo Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

CERo Therapeutics has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CERo Therapeutics and CERo Therapeutics both had 2 articles in the media. CERo Therapeutics' average media sentiment score of 1.22 beat ProPhase Labs' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CERo Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CERo Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. CERo Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
ProPhase Labs	-825.01%	-482.05%	-88.90%

CERo Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 336,978.65%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CERo Therapeutics is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CERo Therapeutics beats ProPhase Labs on 9 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to Biophytis?

ProPhase Labs (NASDAQ:PRPH) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ProPhase Labs has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

In the previous week, ProPhase Labs had 2 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for Biophytis. ProPhase Labs' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Biophytis	Neutral

Biophytis has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Biophytis' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Biophytis	N/A	N/A	N/A

Biophytis has lower revenue, but higher earnings than ProPhase Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Summary

Biophytis beats ProPhase Labs on 5 of the 9 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$190K	$12.40B	$7.25B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	0.00	797.58	275.29	26.14
Price / Sales	0.03	751.21	576.85	85.23
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	0.00	10.71	11.22	6.33
Net Income	-$53.36M	$2.84B	$3.50B	$382.15M
7 Day Performance	N/A	-0.94%	-0.89%	-1.40%
1 Month Performance	N/A	-3.67%	-4.02%	-3.35%
1 Year Performance	N/A	-3.97%	7.13%	1.49%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	N/A	$0.01 -10.0%	N/A	-99.8%	$190K	$5.06M	N/A	130	News Coverage Gap Down
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
PRFX PainReform	1.2259 of 5 stars	$0.89 +1.0%	N/A	-86.5%	$770K	$20K	N/A	7	News Coverage Short Interest Decrease
CMND Clearmind Medicine	1.0241 of 5 stars	$5.84 -2.7%	N/A	-99.8%	$760K	N/A	N/A	4	News Coverage Short Interest Decrease Gap Down
CERO CERo Therapeutics	1.5171 of 5 stars	$0.01 -2.1%	$30.00 +322,480.6%	-99.7%	$666K	N/A	N/A	8	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. ATHX, PRFX, CMND, CERO, and BPTSY

How does ProPhase Labs compare to Athersys?

Summary

How does ProPhase Labs compare to PainReform?

Summary

How does ProPhase Labs compare to Clearmind Medicine?

Summary

How does ProPhase Labs compare to CERo Therapeutics?

Summary

How does ProPhase Labs compare to Biophytis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. ATHX, PRFX, CMND, CERO, and BPTSY

How does ProPhase Labs compare to Athersys?

Do insiders & institutionals hold more shares of ATHX or PRPH?

Is ATHX or PRPH more profitable?

Which has more volatility and risk, ATHX or PRPH?

Does the media refer more to ATHX or PRPH?

Which has stronger earnings and valuation, ATHX or PRPH?

Summary

How does ProPhase Labs compare to PainReform?

Do analysts rate PRPH or PRFX?

Does the media refer more to PRPH or PRFX?

Do insiders & institutionals believe in PRPH or PRFX?

Which has more volatility and risk, PRPH or PRFX?

Is PRPH or PRFX more profitable?

Which has better valuation and earnings, PRPH or PRFX?

Summary

How does ProPhase Labs compare to Clearmind Medicine?

Do insiders and institutionals hold more shares of PRPH or CMND?

Is PRPH or CMND more profitable?

Does the media prefer PRPH or CMND?

Which has more risk and volatility, PRPH or CMND?

Which has higher valuation and earnings, PRPH or CMND?

Summary

How does ProPhase Labs compare to CERo Therapeutics?

Which has more volatility & risk, CERO or PRPH?

Which has stronger valuation & earnings, CERO or PRPH?

Do insiders & institutionals have more ownership in CERO or PRPH?

Does the media refer more to CERO or PRPH?

Is CERO or PRPH more profitable?

Do analysts prefer CERO or PRPH?

Summary

How does ProPhase Labs compare to Biophytis?

Do institutionals and insiders hold more shares of PRPH or BPTSY?

Which has more volatility & risk, PRPH or BPTSY?

Does the media prefer PRPH or BPTSY?

Is PRPH or BPTSY more profitable?

Which has stronger earnings and valuation, PRPH or BPTSY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools